BC Global Opportunities IX LP and Others Report 5.51% Ownership in BridgeBio Oncology Therapeutics, Inc.

BC Global Opportunities IX LP, BC General Partner, LP, BC Capital Management Limited, and Tan Kuangming have reported a 5.51% ownership in BridgeBio Oncology Therapeutics, Inc. Each entity holds 4,365,747 shares of common stock. The filing, made under Rule 13d-1(c), indicates that the shares are not held for the purpose of influencing the control of the issuer. The reporting entities are based in the British Virgin Islands and Hong Kong. The filing was signed by Freeman Szeto, Operation Manager for BC Global Opportunities IX LP, BC General Partner, LP, and BC Capital Management Limited, and by Tan Kuangming, Director.